Palvella Therapeutics Inc... (PVLA)
26.89
1.44 (5.66%)
At close: Apr 22, 2025, 3:59 PM
26.91
0.07%
After-hours: Apr 22, 2025, 04:05 PM EDT
5.66% (1D)
| Bid | 26.26 |
| Market Cap | 296.29M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -9.25M |
| EPS (ttm) | -7.83 |
| PE Ratio (ttm) | -3.43 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 27.44 |
| Volume | 129,363 |
| Avg. Volume (20D) | 71,214 |
| Open | 25.74 |
| Previous Close | 25.45 |
| Day's Range | 24.92 - 27.95 |
| 52-Week Range | 6.20 - 29.27 |
| Beta | -23.17 |
About PVLA
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It als...
Industry Biotechnology
Sector Healthcare
IPO Date Jan 2, 2015
Employees 14
Stock Exchange NASDAQ
Ticker Symbol PVLA
Website https://palvellatx.com
Analyst Forecast
According to 7 analyst ratings, the average rating for PVLA stock is "Buy." The 12-month stock price forecast is $45, which is an increase of 67.35% from the latest price.
Stock Forecasts3 weeks ago
-15.72%
Palvella Therapeutics shares are trading lower on ...
Unlock content with
Pro Subscription
2 months ago
+6.26%
Palvella Therapeutics shares are trading higher after TD Cowen initiated coverage on the stock with a Buy rating and announced a price target of $44.